Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XOMA. Bull or Bear? -- Ignore unavailable to you. Want to Upgrade?

To: Bluegreen who wrote (12374)	12/2/1999 11:02:00 PM
From: aknahow	Read Replies (1) \| Respond to of 17367

I would like to see an analysis of the information to date from the various trials. I have no way of knowing which approach looks better. I did think that the money losing Bloomberg web site, wrongly, seems to assume Biogen will get to the market before competing products. (That is if any of them get there.) BTW I did not spot the Bloomberg article. It was called to my attention.

To: Bluegreen who wrote (12374)	12/2/1999 11:28:00 PM
From: Cacaito	Read Replies (1) \| Respond to of 17367

Do you mean DNA psoriasis drug? Did IPIC give the drug for peanuts? seems that the market thinks the opposite. Ceraxon was rejected by FDA (kindly did not accept the NDA), the drug hardly work, very inconsistent results, it has been used in Spain and Japan (known well for approving garbage drugs)for more than a decade, and I have not seen stories of the great outcomes in stroke in those countries. Do you know that the best conducted studies on Ceraxon worldwide are the IPIC studies in the US, the same that got rejected by FDA? (ok, not rejected, kindly not accepted NDA). IPIC maybe took Takeda for a ride, Do you know that the 500 mg "work", 1000 did not, 2000 did? that in MRI study part infarct volume was smaller/better in placebo than the drug group. But lets see what the 899 patient study showed (kind of lets make it big now like bpi/trauma/pIII and show the real thing). BUT maybe Takeda already peak at study results. xoma's deal is so good with.... nobody, look at the Allergan thing so good they are leaving the development of the drug for year 2000/2001, wow, great interest!!! Look at Medarex, another Mab mouse, and xoma is getting no respect for their well established Mab technology, proven very clearly with IDEC Rituxan (a xoma give away with no royalties, at least IPIC will get royalties). Sometimes (sometimes only) I think xoma must be very undervalued since every Mab company is 4 to 10 times xoma's market value (PDLI, ABGX, MEDX, CNTO), or xoma is highly ineffectively managed.